Cite
HARVARD Citation
Jiang, Q. et al. (n.d.). Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance. Leukemia & lymphoma. 56 (7), pp. 2075-2081. [Online].